Sanofi, Bridgewater, NJ, 13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 14 Sanofi, Chilly-Mazarin, France. RATIONALE: Dupilumab, a human IL-4R-a mAb inhibiting IL-4 and IL-13, key drivers of type 2-mediated inflammation, is approved for uncontrolled moderate-to-severe atopic dermatitis in adults and in the USA for patients aged > _12 years with moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. In a phase 2a study, dupilumab improved endoscopic, radiologic, clinical, and patient-reported outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) patients. For the first time we report results from a phase 3 dupilumab study (SINUS-24; NCT02912468) in severe CRSwNP patients (with/without comorbid asthma) on daily intranasal mometasone furoate (MFNS). METHODS: Adults with CRSwNP previously treated with systemic corticosteroids (SCS) and/or surgery (n 5 276) were randomized 1:1 to subcutaneous dupilumab 300mg or placebo every 2 weeks for 24 weeks. Outcomes included change from baseline to Week 24 in nasal polyp score (NPS), patient-reported nasal congestion (NC), CT Lund-Mackay (LMK), UPSIT smell test, SNOT-22, FEV 1 , and ACQ-6 scores. ) from baseline to Week 24 (LS-mean differences vs placebo). Dupilumab treatment reduced SCS use/NP surgery (P<0.001), and in comorbid asthma patients (58.3%) improved lung function (FEV 1 ; P<0.001) and asthma control (ACQ-6; P<0.0001). The most common adverse event occurring at higher frequency with dupilumab was epistaxis (7.7% vs 3.0% placebo). CONCLUSIONS: Add-on dupilumab to MFNS significantly improved endoscopic, radiologic, clinical, and patient-reported sino-nasal outcomes, and asthma outcome measures in severe CRSwNP patients, and was welltolerated. It is critical to understand the potential impact of asthma and asthma control on the course of pregnancy. METHODS: We conducted a cohort study within the Truven MarketScan Commercial Claims and Encounters Database for 2011-2015. We identified asthma based on diagnoses and treatments and assessed asthma control based on exacerbations (defined as hospitalizations, emergency room admissions, or rescue oral corticosteroid dispensations). We evaluated the proportion of pregnancies ending in livebirth, stillbirth, spontaneous abortion, and termination, and the proportion of liveborn infants with preterm birth, small for gestational age, neonatal intensive care unit admission, and congenital malformations. We assessed the frequency of each of these outcomes for women with and without asthma during pregnancy, and by indicators of control. RESULTS: We identified 29,882 pregnancies (2.9%) with asthma, 18% of which had exacerbations during pregnancy. The proportion of livebirths was 74% in women without asthma, 71% in women with well-controlled asthma and 66% in women with asthma exacerbations early in pregnancy. Among livebirths, there were slightly higher proportions of all adverse fetal outcomes for pregnancies with asthma exacerbations compared to those with well-controlled asthma or without asthma. The proportion of infants with major congenital malformations was 4.4% among pregnancies without asthma, 4.9% in those with well-controlled asthma and 5.8% in those with asthma exacerbations. CONCLUSIONS: Maternal asthma during pregnancy was associated with a slightly elevated risk of adverse fetal outcomes, particularly when it was poorly controlled. Reasons for this association were explored.
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